Livzon pharmaceutical products added to national reimbursement drug list

Livzon Pharmaceutical Group Inc. has confirmed the inclusion of 194 of its products in the National Reimbursement Drug List (2025), effective January 1, 2026. This comprises 92 drugs in Category A and 102 in Category B. Aripiprazole Microspheres for Injection was included for the first time via negotiation, and a new indication was added for Triptorelin Acetate Microspheres for Injection. Additionally, Ilaprazole Sodium for Injection successfully renewed its inclusion.

The company anticipates these inclusions will broaden its market reach and improve drug accessibility, positively impacting future operating performance. No products from the group were removed from the NRDL.

While the NRDL updates are expected to be beneficial, the company states no material impact on current period operating performance is anticipated. Investors are advised to consider potential influences from pharmaceutical industry policies and market conditions.